<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-IVH0925Q</identifier><date>2015</date><creator>Štuhec, Matej</creator><relation>documents/doc/I/URN_NBN_SI_doc-IVH0925Q_001.pdf</relation><relation>documents/doc/I/URN_NBN_SI_doc-IVH0925Q_001.txt</relation><format format_type="issue">1</format><format format_type="volume">66</format><format format_type="type">article</format><format format_type="extent">str. 28-34</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">3818609</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-IVH0925Q</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">antiepileptična zdravila</subject><subject language_type_id="slv">antiepileptiki</subject><subject language_type_id="slv">Klinična farmacija</subject><subject language_type_id="slv">klinični farmacija</subject><subject language_type_id="slv">neželeni učinki</subject><title>how to approach</title><title>kako pristopiti</title><title>Optimizacija zdravljenja z antiepileptičnimi zdravili glede na neželene učinke zdravil</title><title>Optimization of antiepileptic drug pharmacotherapy related to adverse drug effects</title></Record>